4/30/2013

Carotid stent therapy has been shown to be as effective as surgery in low-risk asymptomatic patients, yet CMS has upheld a 25-year-old noncoverage stance, without explanation, writes Dr. Christopher White, SCAI's immediate past president. Many observers believe CMS' position is the result of "turf battles," which have permitted the agency to disregard scientific results and to stifle medical innovation, Dr. White writes. The result, he says, is that patients are unable to opt for the treatment that may be best for them.

Related Summaries